Eli Lilly and Company
Eli Lilly and Company demonstrates strong growth and profitability, reflected in high scores for these categories. The company's business quality and capital allocation also score well. However, financial strength and valuation are areas of concern, with lower scores indicating potential risks or headwinds.
Business Performance (CAGR)
Valuation Snapshot
Financial Health
Profitability Metrics
Cash Flow Intelligence
Intrinsic Value
PremiumEstimated Intrinsic Value & DCF Fair Value are available with Premium plans.
AI Business Verdict
Eli Lilly and Company presents a compelling case for strong business performance and growth, underpinned by excellent profitability and effective capital allocation. However, concerns regarding its financial strength, particularly the debt-to-equity ratio, and its current valuation suggest that the company's shares are trading at a significant premium to its intrinsic value. While growth trajectory is strong, potential business analysts should weigh the high valuation against the financial leverage.
- Exceptional growth rates across revenue, PAT, EPS, and FCF.
- High profitability metrics including Net Margin, Operating Margin, ROE, and ROCE.
- Strong business quality and effective capital allocation.
- Significant operating cash flow generation.
Balance Sheet
Eli Lilly and Company has an adequate but tight balance sheet — leverage and liquidity warrant monitoring.
Capacity to fund growth, withstand downturns and return capital.
- Eli Lilly and Company has an adequate but tight balance sheet — leverage and liquidity warrant monitoring.
- Balance sheet is functional but shows no standout strengths
- Elevated debt-to-equity ratio
- Long working capital cycle
- Large 'other assets' bucket — investigate composition